Reviewing LENZ Therapeutics (LENZ) and Its Rivals

LENZ Therapeutics (NASDAQ:LENZ) is one of 291 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it contrast to its peers? We will compare LENZ Therapeutics to related businesses based on the strength of its earnings, dividends, risk, analyst recommendations, institutional ownership, profitability and valuation.

Earnings and Valuation

This table compares LENZ Therapeutics and its peers top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
LENZ Therapeutics	N/A	-$124.65 million	-1.02
LENZ Therapeutics Competitors	$543.23 million	-$37.31 million	5.89

LENZ Therapeutics’ peers have higher revenue and earnings than LENZ Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Insider and Institutional Ownership

54.3% of LENZ Therapeutics shares are owned by institutional investors. Comparatively, 50.3% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 38.4% of LENZ Therapeutics shares are owned by company insiders. Comparatively, 16.1% of shares of all “Biological products, except diagnostic” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares LENZ Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
LENZ Therapeutics	N/A	-33.12%	-27.96%
LENZ Therapeutics Competitors	-4,499.00%	-224.48%	-45.27%

Volatility and Risk

LENZ Therapeutics has a beta of 0.2, indicating that its stock price is 80% less volatile than the S&P 500. Comparatively, LENZ Therapeutics’ peers have a beta of 1.00, indicating that their average stock price is 0% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations for LENZ Therapeutics and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENZ Therapeutics	0	0	5	0	3.00
LENZ Therapeutics Competitors	1427	4560	11940	206	2.60

LENZ Therapeutics presently has a consensus price target of $31.33, indicating a potential upside of 97.19%. As a group, “Biological products, except diagnostic” companies have a potential upside of 124.75%. Given LENZ Therapeutics’ peers higher probable upside, analysts plainly believe LENZ Therapeutics has less favorable growth aspects than its peers.

Summary

LENZ Therapeutics beats its peers on 7 of the 13 factors compared.

About LENZ Therapeutics

LENZ Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing aceclidine-based eye drop to enhance vision in patients diagnosed with presbyopia. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.